CLYM (Climb Bio) 5-Year EBITDA Growth Rate: 12.80% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLYM Climb Bio Inc CLYM
22 GF Score
Price $17.39
! 3 Warning Signs
View Full Analysis

What is Climb Bio 5-Year EBITDA Growth Rate?

Climb Bio CLYM -0.40% 22 5-Year EBITDA Growth Rate is 12.80% as of Jun. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Climb Bio's EBITDA per Share for the three months ended in Jun. 2026 was $-0.20.

During the past 3 years, the average EBITDA Per Share Growth Rate was 16.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Climb Bio was 39.90% per year. The lowest was -35.70% per year. And the median was 1.30% per year.

Climb Bio  (NAS:CLYM) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Climb Bio 5-Year EBITDA Growth Rate Related Terms

CLYM vs DSGN, MNPR, ACRS: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Climb Bio's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Climb Bio's 5-Year EBITDA Growth Rate falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 12.80% mean?
Climb Bio (CLYM) has a 5-Year EBITDA Growth Rate of 12.80% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Climb Bio and its competitors.
Is Climb Bio's 5-Year EBITDA Growth Rate too high?
Climb Bio's current 5-Year EBITDA Growth Rate is 12.80%. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's 5-Year EBITDA Growth Rate compare to DSGN and MNPR?
Climb Bio's 5-Year EBITDA Growth Rate of 12.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Climb Bio and its competitors. Climb Bio's current 5-Year EBITDA Growth Rate is 12.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current 5-Year EBITDA Growth Rate of 12.80%. The current 5-Year EBITDA Growth Rate is 12.80%. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Climb Bio (CLYM), the current 5-Year EBITDA Growth Rate is 12.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.39
Price